Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | FABP7 | O15540 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20971992 | 1.00 | CYP1A2 (0.35) | CYP1A2TSHRPPARGPPARACYP2C19 | |
| SCHEMBL23525180 | 0.86 | CYP1A2 (0.35) | CYP1A2TSHRPPARGPPARAFABP5 | |
| SCHEMBL1198343 | 0.83 | CYP1A2 (0.37) | CYP1A2TSHRPPARGPPARAFABP5 | |
| SCHEMBL16933080 | 0.83 | CYP1A2 (0.37) | CYP1A2TSHRPPARGPPARAFABP5 | |
| SCHEMBL17505605 | 0.81 | HTR2A (0.37) | CYP1A2TSHRPPARGPPARAFABP5 | |
| SCHEMBL17505607 | 0.81 | HTR2A (0.37) | CYP1A2TSHRPPARGPPARAFABP5 | |
| SCHEMBL22804049 | 0.78 | CYP1A2 (0.41) | CYP1A2TSHRPPARGPPARA | |
| SCHEMBL23525418 | 0.77 | BCHE (0.34) | CYP1A2TSHRPPARGPPARAPOLB | |
| SCHEMBL22344856 | 0.76 | KMT2A (0.44) | CYP1A2CYP2C19KMT2A | |
| SCHEMBL22344859 | 0.76 | KMT2A (0.44) | CYP1A2CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210330651-A1 | ESTROGEN RECEPTOR MODULATORS | RECURIUM IP HOLDINGS, LLC | 2021-10-28 | — | — | US | disclosed |
| US-11065234-B2 | Estrogen receptor modulators | RECURIUM IP HOLDINGS, LLC (US) | 2021-07-20 | — | — | US | disclosed |
| US-11065233-B2 | Estrogen receptor modulators | RECURIUM IP HOLDINGS, LLC (US) | 2021-07-20 | — | — | US | disclosed |
| US-10959989-B2 | Estrogen receptor modulators | RECURIUM IP HOLDINGS, LLC (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200261428-A1 | ESTROGEN RECEPTOR MODULATORS | KALYRA PHARMACEUTICALS, INC. | 2020-08-20 | — | — | US | disclosed |
| US-20200261430-A1 | ESTROGEN RECEPTOR MODULATORS | KALYRA PHARMACEUTICALS, INC. | 2020-08-20 | — | — | US | disclosed |
| US-20200261429-A1 | ESTROGEN RECEPTOR MODULATORS | KALYRA PHARMACEUTICALS, INC. | 2020-08-20 | — | — | US | disclosed |
| US-20190142811-A1 | ESTROGEN RECEPTOR MODULATORS | RECURIUM IP HOLDINGS, LLC | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11065233-B2 | Estrogen receptor modulators | ESR2, GPER1, ESRRG | CYP1A2 292/4885TSHR 125/4885PPARG 101/4885 |
| US-20200261430-A1 | ESTROGEN RECEPTOR MODULATORS | ESR2, GPER1, ESRRG | CYP1A2 292/4885TSHR 125/4885PPARG 101/4885 |
| US-20200261428-A1 | ESTROGEN RECEPTOR MODULATORS | ESR2, GPER1, ESRRG | CYP1A2 292/4885TSHR 125/4885PPARG 101/4885 |
| US-20190142811-A1 | ESTROGEN RECEPTOR MODULATORS | ESR2, GPER1, ESRRG | CYP1A2 292/4885TSHR 125/4885PPARG 101/4885 |
| US-20200261429-A1 | ESTROGEN RECEPTOR MODULATORS | ESR2, GPER1, ESRRG | CYP1A2 292/4885TSHR 125/4885PPARG 101/4885 |
| US-10959989-B2 | Estrogen receptor modulators | ESR2, GPER1, ESRRG | CYP1A2 292/4885TSHR 125/4885PPARG 101/4885 |
| US-20210330651-A1 | ESTROGEN RECEPTOR MODULATORS | ESR2, GPER1, ESRRG | CYP1A2 292/4885TSHR 125/4885PPARG 101/4885 |
| US-11065234-B2 | Estrogen receptor modulators | ESR2, GPER1, ESRRG | CYP1A2 292/4885TSHR 125/4885PPARG 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.